Uncategorized

Oak Hill takes SPAC track to Nasdaq with Roche asset in tow

Published

on

Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version